Abbvie Inc(ABBV-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low221.72
Day High227.14
Open:224.80
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Zacks Investment Research
Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike
Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike
Tipranks
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), GMR Solutions, Inc. Class A (GMRS) and Cullinan Management (CGEM)
Zacks Investment Research
Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month?
Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month?
Motley Fool
Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500?
Tipranks
AbbVie Ends Early Lung Cancer Trial for ABBV-647, Trimming One Oncology Upside Lever
Tipranks
AbbVie Completes Real World Upadacitinib Study in China: What Investors Should Watch
Tipranks
AbbVie Advances ABBV-932 With Completed Bioavailability Study, Supporting Long-Term Pipeline Value
Motley Fool
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech
Stock Target Advisor
Market Analysis for June 4th, 2026
AbbVie (ABBV) gained attention after UK regulators recommended approval of its targeted ovarian cancer therapy Elahere under a confidential NHS agreement, reinforcing momentum in precision on
Tipranks
AbbVie’s RINVOQ Safety Study In Japan: What The Latest Update Means For ABBV Investors
Zacks Investment Research
Does Decnupaz Approval Validate ABBV's ADC Strategy in Oncology?
Does Decnupaz Approval Validate ABBV's ADC Strategy in Oncology?
Tipranks
Analysts’ Top Healthcare Picks: TG Therapeutics (TGTX), AbbVie (ABBV)
Motley Fool
The Best Stocks to Invest $500 in Right Now
Zacks Investment Research
AbbVie Gets EU Nod for Aquipta as Acute Treatment for Migraine
AbbVie Gets EU Nod for Aquipta as Acute Treatment for Migraine
Tipranks
Analysts Offer Insights on Healthcare Companies: Astellas Pharma (OtherALPMF), AbbVie (ABBV) and Replimune Group (REPL)
Motley Fool
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Year, According to Wall Street
Motley Fool
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic
Motley Fool
The S&P 500 Is Expensive, but These 3 Dividend Stocks Still Look Like Bargains
Tipranks
Piper Sandler Reaffirms Their Buy Rating on AbbVie (ABBV)

Profile

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.